Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 10,235 shares of the business’s stock in a transaction on Monday, October 29th. The shares were acquired at an average cost of $14.98 per share, with a total value of $153,320.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ ODT traded down $0.45 during trading on Tuesday, reaching $14.52. The stock had a trading volume of 34,725 shares, compared to its average volume of 53,676. Odonate Therapeutics Inc has a fifty-two week low of $14.06 and a fifty-two week high of $32.00. The stock has a market capitalization of $408.59 million and a PE ratio of -6.29.
Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Tuesday, October 23rd. The company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.02). As a group, analysts expect that Odonate Therapeutics Inc will post -3.49 EPS for the current year.
Separately, Zacks Investment Research cut Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $31.00.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Featured Story: Using the New Google Finance Tool
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.